Three drugs that inhibit the immunoglobulin G (IgG) neonatal fragment crystallizable receptor (FcRn) were approved to treat ...
The NDA is supported by data from part A of the phase 2 PROSPECT trial, which evaluated tirabrutinib in 48 adult patients with R/R PCNSL.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results